Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Abington Memorial Hospital
mi
from
Abington, PA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Avera Cancer Institute
mi
from
Sioux Falls, SD
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
John Muir Medical Center-Walnut Creek
mi
from
Walnut Creek, CA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
John Muir Medical Center-Walnut Creek
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
University of Colorado Hospital
mi
from
Aurora, CO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Memorial University Medical Center
mi
from
Savannah, GA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Good Samaritan Regional Health Center
mi
from
Mount Vernon, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Good Samaritan Regional Health Center
mi
from
Mount Vernon, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Northwestern Medicine Cancer Center Warrenville
mi
from
Warrenville, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Northwestern Medicine Cancer Center Warrenville
mi
from
Warrenville, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Lake Huron Medical Center
mi
from
Port Huron, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Lake Huron Medical Center
mi
from
Port Huron, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Mercy Hospital-Joplin
mi
from
Joplin, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Mercy Hospital-Joplin
mi
from
Joplin, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Mercy Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Mercy Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Cox Medical Center South
mi
from
Springfield, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Women and Infants Hospital
mi
from
Providence, RI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease
Status: Enrolling
Updated:  3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease
Status: Enrolling
Updated: 3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials